ArticleExperimental and therapeutic medicine2025
Primary endobronchial epithelial-myoepithelial carcinoma: A case report and literature review.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary epithelial-myoepithelial carcinoma (P-EMC) is a rare type of salivary gland tumour of the lung. Due to its rarity and lack of long-term follow-up data, there is no established standard for optimal treatment or duration of follow-up. The present study reports the case of a 58-year-old female patient with P-EMC originating from the middle part of the bronchus and presenting as an endobronchial mass in the left superior lobe. Transbronchial forceps biopsy was performed on the visible neoplasm in the left superior lobe, which revealed atypical epithelial cells with a possible diagnosis of mucoepidermoid carcinoma. The patient subsequently underwent left upper lobectomy with mediastinal lymph node dissection. The decision for resection was made based on the absence of abnormalities in the patient's head and neck MRI scan, bone scintigraphy and contrast-enhanced whole-body CT scan, along with the consensus reached by the multidisciplinary treatment team. Final histopathology of the resected specimen confirmed P-EMC. The patient remained free of recurrence and metastasis 5 years post-surgery. Diagnosis of P-EMC from transbronchial forceps biopsy samples is difficult due to its rarity, insufficient sampling and dual histological phenotype. The current study reported a rare case of primary P-EMC initially suspected to be mucoepidermoid carcinoma based on biopsy. Postoperative pathology confirmed the diagnosis of P-EMC. Based on this case and a literature review, for endobronchial EMC lesions confined to the bronchus measuring <2 cm without metastasis, bronchoscopic intervention or video-assisted thoracoscopic segmentectomy may be viable therapeutic alternatives. For nonmetastatic central lesions >2 cm, lobectomy or wedge resection should be considered to avoid the more traumatic pneumonectomy whenever possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.